Lancet Glob Health 2022; 10: e491–500
Myanmar’s transition to a market‐based economy is accompanied by rapid development of the private manufacturing sector, which has large potential for improving economic growth. The overall success of the sector, however, should not be taken for granted. Future advances will greatly depend on th...e policy and business environment in which manufacturing activities take place. It is, therefore, important to better understand the business environment and help inform policies conducive to sustainable economic growth.
more
Despite recent global declines, under-five mortality remains high in many of the poorest countries. Barriers to timely
quality care, including user fees, distance to facilities and the availability of trained health workers and medical supplies,
hinder progress in further reducing morbidity and m...ortality
more
Over the period 2015 to 2019, scaling up a package of selected nutrition-specific and nutrition sensitive interventions to cover 90 per cent of Sudan would:
- Reduce the under-five mortality rate to 49/1,000 live births
- Reduce the prevalence of stunting to 25 per cent
- Reduce the ...prevalence of wasting (global acute malnutrition – GAM) to 6 per cent
- Increase exclusive breastfeeding to 63 per cent
- Reduce iron deficiency anaemia among pregnant women to 26 per cent.
more
Guía práctica para mejorar la calidad de la atención mediante los servicios de agua, saneamiento e higiene en los establecimientos de salud
What countries need: Investments needed for 2010 targets
Budgetary mechanisms in highly affected countries
PLoS ONE 15(1): e0228135.
The introduction of “Treat All” (TA) has been promoted to increase the effectiveness of HIV/AIDS treatment by having patients initiate antiretroviral therapy at an earlier stage of their illness. The impact of introducing TA on the unit cost of treatment has been less ...clear. The following study evaluated how costs changed after Namibia’s introduction of TA in April 2017.
more
To examine how health aid is spent and channelled, including the distribution of resources across countries and between
subsectors. Our aim was to complement the many qualitative critiques of health aid with a quantitative review and to provide insights on the level of development assistance availa...ble to recipient countries to address their health and health development needs.
more
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):858–864.Namibia ranks among the 30 high TB burden countries worldwide. Here, we report results of the second nationwide anti-TB drug resistance survey. To assess the prevalence and trends of multidrug-resistant TB (MDR-TB) in Namibia.
From 2014 to 2015, pat...ients with presumptive TB in all regions of Namibia had sputum subjected to mycobacterial culture and phenotypic drug susceptibility testing (DST) for rifampicin, isoniazid, ethambutol and streptomycin if positive on smear microscopy and/or Xpert MTB/RIF.
more
The document “Malaria Elimination Programme Review, India 2022”, published by the WHO Country Office for India, provides an in-depth assessment of India’s progress toward malaria elimination. It evaluates the structure, implementation, and effectiveness of national and subnational malaria prog...rams, focusing on surveillance, diagnosis, treatment, vector control, and community engagement. The review identifies strengths, challenges, and areas for improvement, offering evidence-based recommendations to accelerate India's efforts to eliminate malaria by 2030.
more
The COVID-19 pandemic demonstrated that
the world was not well prepared to respond
to an infectious disease threat of this magnitude. Countries across all socioeconomic and development categories have struggled
to implement effective national responses. Substantial amounts of additional investmen...t are required to support the development of country capacities to prevent, detect and respond to both existing and emerging
infectious disease threats. Prior research efforts have estimated that between US$96 and $204billion is required, globally, to
advance country-level health security capacities, with US$63–131billion needed over a 3-year period. Given the substantial costs
of ongoing COVID-19 response, estimated to
be over US$12.5trillion through 2024, and an estimated 12.1–22.7million excess deaths, globally, due to COVID-19 as of January 2022,
the importance and potential return on investment of such upfront investments in capacity building are more evident than ever before.
more